Ewa Wąsik-Szczepanek

Ewa Wąsik-Szczepanek

Auto-generated profile, based on publicly available information

Ewa Wąsik-Szczepanek

Med Univ, Dept Haematooncol & Bone Marrow Transplantat, Aleje Raclawickie 1, PL-20059 Lublin, Poland

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2006 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
IHIwona Hus
Iwona Hus
MPMonika Podhorecka
Monika Podhorecka
Agnieszka Bojarska-JunakAgnieszka Bojarska-Junak
Agnieszka Bojarska-Junak
JRJacek Roliński
Jacek Roliński
MSM. Schmitt
M. Schmitt
ADA. Dmoszyńska
A. Dmoszyńska
Background: B-cell chronic lymphocytic leukaemia (B-CLL) is a disease with a highly variable clinical course; some patients never need treatment, while others require intensive treatment early after diagnosis. Recently, some new prognostic factors, such as IgVH mutational status, ZAP-70 and the expression of CD38 in leukaemic cells were introduced to identify attenuated versus progressive types of CLL bearing the potential to facilitate risk-adapted treatment strategies. Patients and methods: To evaluate the clinical value of ZAP-70 and CD38 as predictors of disease progression we assessed the expression of these markers by the flow cytometry method in 156 B-CLL patients. Results and conclusions: Both ZAP-70 and CD38 expression were shown to predict the clinical course of the disease, while ZAP-70 expression appeared to be more predictive than CD38 expression and more relevant in defining the cases of B-CLL responsive or refractory to first line chemotherapy. A simultaneous evaluation of ZAP-70 and CD38 expression allowed distinguishing the patients groups with the most favourable prognosis as well as those with the worst. Taken together we recommend assessing both ZAP-70 and CD38 protein expression for the definition of prognostic subgroups in patients with B-CLL

1 April 2013 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
AFAgata Filip
Agata Filip
BCBogumiła Ciseł
Bogumiła Ciseł
DKDorota Koczkodaj
Dorota Koczkodaj
EWEwa Wąsik-Szczepanek
Ewa Wąsik-Szczepanek
TPTomasz Piersiak
Tomasz Piersiak
ADAnna Dmoszyńska
Anna Dmoszyńska

1 October 2009 in Leukemia Research
Verified
Journal Article
Closed access
Agnieszka Bojarska-JunakAgnieszka Bojarska-Junak
Agnieszka Bojarska-Junak
IHIwona Hus
Iwona Hus
SCSylwia Chocholska
Sylwia Chocholska
EWEwa Wąsik-Szczepanek
Ewa Wąsik-Szczepanek
MSMałgorzata Sieklucka
Małgorzata Sieklucka
JRJacek Roliński
Jacek Roliński

14 May 2009 in Leukemia
Verified
Journal Article
Closed access
PDF file
Krzysztof GiannopoulosKrzysztof Giannopoulos
Krzysztof Giannopoulos
ADA Dmoszynska
A Dmoszynska
MKM Kowal
M Kowal
EWE Wąsik-Szczepanek
E Wąsik-Szczepanek
Agnieszka Bojarska-JunakAgnieszka Bojarska-Junak
Agnieszka Bojarska-Junak
LBL Bullinger
L Bullinger

12 October 2016 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
AFAgata Filip
Agata Filip
AGAnna Grenda
Anna Grenda
SPSylwia Popek-Marciniec
Sylwia Popek-Marciniec
DKDorota Koczkodaj
Dorota Koczkodaj
MMMałgorzata Michalak-Wojnowska
Małgorzata Michalak-Wojnowska
Krzysztof GiannopoulosKrzysztof Giannopoulos
Krzysztof Giannopoulos
Expression of microRNAs is altered in cancer. Circulating miRNA level assessed in body fluids commonly reflects their expression in tumor cells. In leukemias, however, both leukemic and nonleukemic cells compose circulating miRNA expression profile of peripheral blood. The latter contribution to extracellular miRNA pool may result in specific microenvironmental signaling, which promotes proliferation and survival. In our study, we used qT-PCR to assay peripheral blood serum of 22 chronic lymphocytic leukemia (CLL) patients for the expression of 84 miRNAs associated with activation and differentiation of B and T lymphocytes. Results were analyzed regarding the most important prognostic factors. We have found that the general expression of examined miRNAs in CLL patients was lower as compared to healthy volunteers. Only miR-34a-5p, miR31-5p, miR-155-5p, miR-150-5p, miR-15a-3p, and miR-29a-3p were expressed on a higher level. Alterations of expression observed in CLL patients involved miRNAs associated both with B and T lymphocyte differentiation and activation. The most important discriminating factors for all functional miRNA groups were trisomy 12, CD38 expression, B2M level, WBC, and NOTCH1 gene mutation. Correlation of expression of miRNAs related to T lymphocytes with prognostic factors proves their supportive function in a leukemic microenvironment. Further studies utilizing a larger test group of patients may warrant the identification of circulating miRNAs that are key players in intercellular interactions and should be considered in the design of microenvironment-targeted therapies.

12 December 2013 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
AFAgata Filip
Agata Filip
BCBogumiła Ciseł
Bogumiła Ciseł
EWEwa Wąsik-Szczepanek
Ewa Wąsik-Szczepanek
B-cell chronic lymphocytic leukemia (B-CLL) is one of the most common leukemias among the elderly and, despite many efforts, still stays incurable. Recent studies point to the microenvironment as the critical factor providing leukemic lymphocytes with pro-survival signals. Thus, the neighboring cells appear to be a perfect target for antileukemic therapy. Nurse-like cells (NLCs) largely contribute to CLL microenvironmental support. We developed the CLL lymphocyte/NLC co-culture model for the investigation of microenvironmental interactions. Viability and apoptosis were investigated in CLL lymphocytes treated with dexamethasone (DEX) and chlorambucil (CLB), with and without NLCs’ support. For the first time, the capacity of DEX and CLB to affect NLCs viability was also evaluated. Apoptosis-associated gene expression profiles of leukemic lymphocytes ex vivo and cultured with NLCs were assessed by expression arrays. CLL lymphocytes escaped spontaneous apoptosis for several months when cultured with NLCs. The presence of NLCs significantly reduced apoptosis induced with DEX and CLB (p < 0.001; p = 0.012, respectively), and their protective effect was more evident than the effect of recombinant SDF1. Both DEX and CLB also decreased NLCs viability, but to a lesser extent (mean viability in DEX-treated cultures was 37.79 % in NLCs compared to 29.24 % in lymphocytes). NLCs induced the expression of important anti-apoptotic genes in cultured CLL lymphocytes; median expression of BCL2, SURVIVIN, BCL2A1, and XIAP was significantly higher as compared to ex vivo status. The CLL lymphocyte/NLC co-culture makes up the convenient and close to the natural-state model for studying the relationship between leukemic cells and the microenvironment. Direct cell-to-cell contact with NLCs increases the expression of anti-apoptotic genes in CLL lymphocytes, thus protecting them against induced apoptosis. As the effect of antileukemic drugs is not so apparent in NLCs, the combined therapy targeted at both lymphocytes and the microenvironment should be considered for CLL patients. Simultaneous aiming at the disruption of several different signaling pathways and/or anti-apoptotic proteins may further improve treatment efficiency.